Effect of brimonidine/timolol fixed combination on preventing the short-term intraocular pressure increase after intravitreal injection of ranibizumab

Klinische Monatsblatter fur Augenheilkunde

Volumn 227, Issue 4, 2010, Pages 280-284

  Theoulakis, P E ^a   Lepidas, J ^b   Petropoulos, I K ^c   Livieratou, A ^b   Brinkmann, C K ^d   Katsimpris, J M ^b  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b UNIVERSITY GENERAL HOSPITAL OF PATRAS   (Greece)

^c Ophthalmological Center of Terrassire   (Switzerland)

^d University Eye Clinic Bern   (Switzerland)

Author keywords

Brimonidine; Intraocular pressure elevation; Intravitreal injection; Ranibizumab; Timolol

Indexed keywords

BRIMONIDINE PLUS TIMOLOL; PLACEBO; RANIBIZUMAB;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INTRAOCULAR PRESSURE ABNORMALITY; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; RETINA MACULA AGE RELATED DEGENERATION; SPIKE; TREATMENT INDICATION;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIHYPERTENSIVE AGENTS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; HUMANS; INJECTIONS, INTRALESIONAL; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OCULAR HYPERTENSION; PLACEBO EFFECT; QUINOXALINES; TIMOLOL; TREATMENT OUTCOME; VITREOUS BODY;

EID: 77951616169     PISSN: 00232165     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0029-1245201     Document Type: Article

References (23)

1. Bakri S J., McCannel C A., Edwards A O. et al. Persistent ocular hypertension following intravitreal ranibizumab. Graefes Arch Clin Exp Ophthalmol 2008 246 955-958
2. Bakri S J., Pulido J S., McCannel C A. et al. Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab. Eye 2009 23 181-185
3. Benz M S., Albini T A., Holz E R. et al. Short-term course of intraocular pressure after intravitreal injection of triamcinolone acetonide. Ophthalmology 2006 113 1174-1178 (Pubitemid 43947221)
4. Brown D M., Kaiser P K., Michels M et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006 355 1432-1444 (Pubitemid 44511558)
5. Coden D J., Freeman W R., Weinreb R N. Intraocular pressure response after pneumatic retinopexy. Ophthalmic Surg 1988 19 667-669
6. Dwinger M C., Pieper-Bodeewes I, Eter N et al. Augeninnendruck und Notwendigkeit einer Parazentese unmittelbar nach intravitrealer Triamcinolon-Injektion. Klin Monatsbl Augenheilkd 2005 222 638-642 (Pubitemid 41290798)
7. Falkenstein I A., Cheng L, Freeman W R. Changes of intraocular pressure after intravitreal injection of bevacizumab (avastin). Retina 2007 27 1044-1047 (Pubitemid 350304005)
8. Gragoudas E S., Adamis A P., Cunningham E T. et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004 351 2805-2816 (Pubitemid 40051904)
9. Hariprasad S M., Shah G K., Blinder K J. Short-term intraocular pressure trends following intravitreal pegaptanib (Macugen) injection. Am J Ophthalmol 2006 141 200-201 (Pubitemid 43016199)
10. Heinemann M H. Long-term intravitreal ganciclovir therapy for cytomegalovirus retinopathy. Arch Ophthalmol 1989 107 1767-1772 (Pubitemid 20013138)
11. Hollands H Jr, Wong J, Bruen R et al. Short-term intraocular pressure changes after intravitreal injection of bevacizumab. Can J Ophthalmol 2007 42 807-811
12. Jager R D., Aiello L P., Patel S C. et al. Risks of intravitreous injection: a comprehensive review. Retina 2004 24 676-698
13. Jonas J B., Degenring R F., Kreissig I et al. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology 2005 112 593-598 (Pubitemid 41108858)
14. Kim J E., Mantravadi A V., Hur E Y. et al. Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents. Am J Ophthalmol 2008 146 930-934 e1
15. Konstas A G., Katsimpris I E., Kaltsos K et al. Twenty-four-hour efficacy of the brimonidine/timolol fixed combination versus therapy with the unfixed components. Eye 2008 22 1391-1397
16. Michelson G, Groh M J., Langhans M. Perfusion of the juxtapapillary retina and optic nerve head in acute ocular hypertension. Ger J Ophthalmol 1996 5 315-321 (Pubitemid 126822707)
17. Morlet N, Young S H. Prevention of intraocular pressure rise following intravitreal injection. Br J Ophthalmol 1993 77 572-573 (Pubitemid 23281457)
18. Quigley H A., Anderson D R. Distribution of axonal transport blockade by acute intraocular pressure elevation in the primate optic nerve head. Invest Ophthalmol Vis Sci 1977 16 640-644
19. Rosenfeld P J., Brown D M., Heier J S. et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006 355 1419-1431 (Pubitemid 44511557)
20. Spaide R F., Laud K, Fine H F. et al. Intraviteal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2006 26 383-390 (Pubitemid 44197628)
21. Thompson J T. Cataract formation and other complications of intravitreal triamcinolone for macular edema. Am J Ophthalmol 2006 141 629-637
22. Tsui Y P., Chiang C C., Tsai Y Y. Paracentesis before intravitreal injection of bevacizumab. Can J Ophthalmol 2008 43 239
23. Zamvar U, Dhillon B. Postoperative IOP prophylaxis practice following uncomplicated cataract surgery: a UK-wide consultant survey. BMC Ophthalmol 2005 5 24 (Pubitemid 41512673)